Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine in Hospitalized COVID-19 Patients
NCT04504240Phase 3Completed
- Sponsor
- Chattogram General Hospital
- Start
- Aug 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of famotidine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Chattogram General Hospital. Primary endpoints: Time to Clinical Improvement at 30 days and Time to symptomatic recovery at 30 days. Started Aug 2020; status: completed.
02
Drugs
famotidine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04504240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504240.